ESLA EBITDA | ESTRELLA IMMUNOPHARMA, INC.

ESTRELLA IMMUNOPHARMA, INC. (ESLA) EBITDA

2026-06-30: Basis Reported; EBITDA (m); Operating income -$2.08M; Depreciation and amortization (m).
2026-03-31: Basis Reported; EBITDA (m); Operating income -$2.29M; Depreciation and amortization (m).
2025-09-30: Basis Reported; EBITDA (m); Operating income -$4.80M; Depreciation and amortization (m).
2025-06-30: Basis Reported; EBITDA (m); Operating income -$5.54M; Depreciation and amortization (m).

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	(m)	-$2.08M	(m)	(m)	(m)	(m)	-$1.78M*	(m)	$1.40M	(m)	(m)
2026-03-31	Reported	(m)	-$2.29M	(m)	(m)	(m)	(m)	-$6.70M	(m)	$1.40M	(m)	(m)
2025-09-30	Reported	(m)	-$4.80M	(m)	(m)	(m)	(m)	-$727.33K*	(m)	$4.15M	(m)	$0.00*
2025-06-30	Reported	(m)	-$5.54M	(m)	(m)	(m)	(m)	-$414.88K*	(m)	$4.66M	(m)	$850.00
2025-03-31	Reported	(m)	-$2.10M	(m)	(m)	(m)	(m)	-$465.98K	(m)	$1.41M	(m)	$13.00
2024-09-30	Reported	(m)	-$3.38M	(m)	(m)	(m)	(m)	-$2.22M	(m)	$2.83M	(m)	$0.00*
2024-06-30	Reported	(m)	-$3.95M	(m)	(m)	(m)	(m)	-$291.51K*	(m)	$3.52M	(m)	$1.63K
2024-03-31	Reported	(m)	-$469.53K	(m)	(m)	(m)	(m)	-$4.23M	(m)	$25.00K	(m)	(m)
2023-12-31	Reported	(m)	-$1.02M	(m)	(m)	(m)	(m)	-$11.27M*	(m)	$75.46K	(m)	(m)
2023-09-30	Reported	(m)	-$1.87M	(m)	(m)	(m)	(m)	-$275.19K	(m)	$483.47K	(m)	(m)
2023-06-30	Reported	(m)	-$169.24K	(m)	(m)	(m)	(m)	-$212.67K*	(m)	(m)	(m)	$21.08K
2023-03-31	Reported	(m)	-$2.74M	(m)	(m)	(m)	(m)	-$275.72K	(m)	$2.62M	(m)	$19.46K
2022-12-31	Reported	(m)	-$2.76M	(m)	(m)	(m)	(m)	-$108.20K*	(m)	$2.61M	(m)	(m)
2022-09-30	Reported	(m)	-$2.89M	(m)	(m)	(m)	(m)	-$1.10M	(m)	$2.61M	(m)	$0.00
2022-06-30	Reported	(m)	-$423.76K	(m)	(m)	(m)	(m)	-$233.44K*	(m)	(m)	(m)	$0.00
2022-03-31	Reported	(m)	-$144.94K	(m)	(m)	(m)	(m)	-$157.14K	(m)	(m)	(m)	$0.00
2021-09-30	Reported	(m)	-$108.11K	(m)	(m)	(m)	(m)	-$15.98K*	(m)	(m)	(m)	$0.00
2021-06-30	Reported	(m)	-$3.56K	(m)	(m)	(m)	(m)	-$6.05K*	(m)	(m)	(m)	$0.00
2021-03-31	Reported	(m)	-$819.00	(m)	(m)	(m)	(m)	-$819.00	(m)	(m)	(m)	$0.00

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	(m)	-$13.06M	(m)	(m)	(m)	(m)	-$1.79M	(m)	$10.25M	(m)	$838.00
2024-09-30	Rolling	(m)	-$8.82M*	(m)	(m)	(m)	(m)	-$18.01M*	(m)	$6.45M*	(m)	(m)
2024-06-30	Reported	(m)	-$7.31M	(m)	(m)	(m)	(m)	-$16.07M	(m)	$4.11M	(m)	$1.63K
2024-06-30	Rolling	(m)	-$7.31M*	(m)	(m)	(m)	(m)	-$16.07M*	(m)	$4.11M*	(m)	(m)
2024-03-31	Rolling	(m)	-$3.53M*	(m)	(m)	(m)	(m)	-$15.99M*	(m)	(m)	(m)	(m)
2023-12-31	Rolling	(m)	-$5.80M*	(m)	(m)	(m)	(m)	-$12.03M*	(m)	(m)	(m)	(m)
2023-09-30	Rolling	(m)	-$7.54M*	(m)	(m)	(m)	(m)	-$871.77K*	(m)	(m)	(m)	(m)
2023-06-30	Reported	(m)	-$11.11M	(m)	(m)	(m)	(m)	-$1.34M	(m)	$10.45M	(m)	(m)
2023-06-30	Rolling	(m)	-$8.55M*	(m)	(m)	(m)	(m)	-$1.70M*	(m)	(m)	(m)	(m)
2023-03-31	Rolling	(m)	-$8.81M*	(m)	(m)	(m)	(m)	-$1.72M*	(m)	(m)	(m)	(m)
2022-12-31	Reported	(m)	-$1.57M	(m)	(m)	(m)	(m)	-$1.04M	(m)	(m)	(m)	$80.65K
2022-12-31	Rolling	(m)	-$6.21M*	(m)	(m)	(m)	(m)	-$1.60M*	(m)	(m)	(m)	(m)
2021-12-31	Reported	(m)	-$249.15K	(m)	(m)	(m)	(m)	-$316.16K	(m)	(m)	(m)	$0.00

Stock Name	Country	Market Cap	PE Ratio
Jasper Therapeutics, Inc. (JSPR)	United States	$0.020B	-0.37
BioCardia, Inc. (BCDA)	United States	$0.016B
DYADIC INTERNATIONAL INC (DYAI)	United States	$0.016B
Passage BIO, Inc. (PASG)	United States	$0.015B	-0.43
Pluri Inc. (PLUR)		$0.014B
INTENSITY THERAPEUTICS, INC. (INTS)	United States	$0.013B	-1.08
BRAINSTORM CELL THERAPEUTICS INC. (BCLI)	United States	$0.013B	-1.05
IN8BIO, INC. (INAB)	United States	$0.012B	-0.76
Senti Biosciences Holdings, Inc. (SNTI)	United States	$0.011B	-0.70
CEL SCI CORP (CVM)	United States	$0.030B	-0.81